Ruth Ladenstein

发表

IT Infrastructure for Merging Data from Different Clinical Trials and Across Independent Research Networks

Günter Schreier, Dieter Hayn, Markus Falgenhauer, 2016, MIE.

Piloting the European Unified Patient Identity Management (EUPID) Concept to Facilitate Secondary Use of Neuroblastoma Data from Clinical Trials and Biobanking

Günter Schreier, Dieter Hayn, Markus Falgenhauer, 2016, eHealth.

PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers

Marco Viceconti, Jordi Mestres, Wolfgang Jentner, 2020, European Radiology Experimental.

A Web-based platform for interdisciplinary biomedical research.

Ruth Ladenstein, Guenter Schreier, Juergen Messmer, 2009, Frontiers in bioscience.

An mHealth system for toxicity monitoring of paediatric oncological patients using Near Field Communication technology

Günter Schreier, Dieter Hayn, Ruth Ladenstein, 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

Electronic Patient Reported Outcomes in Paediatric Oncology - Applying Mobile and Near Field Communication Technology

Günter Schreier, Dieter Hayn, Markus Falgenhauer, 2016, eHealth.

Standardized Data Sharing in a Paediatric Oncology Research Network - A Proof-of-Concept Study

Manolis Tsiknakis, Günter Schreier, Dieter Hayn, 2015, eHealth.

Interoperability Architecture for a Paediatric Oncology European Reference Network

Günter Schreier, Michael Nitzlnader, Ruth Ladenstein, 2016, eHealth.

Challenges for children and adolescents with cancer in Europe: The SIOP-Europe agenda

Ruth Ladenstein, Maria Grazia Valsecchi, Samira Essiaf, 2014, Pediatric blood & cancer.

Standardization of the Immunocytochemical Detection of Neuroblastoma Cells in Bone Marrow

Ruth Ladenstein, Dyanne Rampling, Peter F. Ambros, 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Günter Schreier, Ruth Ladenstein, Henrik Schroeder, 2017, The Lancet. Oncology.

Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.

Ruth Ladenstein, Victoria Castel, A. Cañete, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.

Ruth Ladenstein, Gudrun Schleiermacher, Gian Paolo Tonini, 2009, The Lancet. Oncology.

Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET.

Ruth Ladenstein, A. Vicha, S. Burchill, 2007, European journal of cancer.

High-dose chemotherapy for solid tumors: results of the EBMT.

Ruth Ladenstein, Serge Leyvraz, Jonathan Ledermann, 2002, Critical reviews in oncology/hematology.

Detection of Disseminated Tumor Cells in Neuroblastoma: 3 Log Improvement in Sensitivity by Automatic Immunofluorescence plus FISH (AIPF) Analysis Compared with Classical Bone Marrow Cytology

Ruth Ladenstein, Peter F Ambros, P. Ambros, 2003 .

A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma

Ruth Ladenstein, Gudrun Schleiermacher, Mario Drobics, 2011, Clinical Cancer Research.

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.

Ruth Ladenstein, Peter F. Ambros, Florian Kromp, 2016, Oncotarget.

Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors

Ruth Ladenstein, Peter F. Ambros, Inge M. Ambros, 2016, PloS one.

Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.

Renate Kunert, Ruth Ladenstein, Vito Pistoia, 2005, Molecular immunology.

Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.

Ruth Ladenstein, Jérôme Couturier, Victoria Castel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma

Nathan C. Sheffield, Ruth Ladenstein, Christoph Bock, 2017, Nature Medicine.

Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.

Ruth Ladenstein, Adela Cañete, Victoria Castel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study

Ruth Ladenstein, Gudrun Schleiermacher, Ulrike Pötschger, 2018, Pediatric blood & cancer.

Development of an electronic database for quality assurance of radiotherapy in the International Society of Paediatric Oncology (Europe) high risk neuroblastoma study.

Günter Schreier, Ruth Ladenstein, Jean-Louis Habrand, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Disseminated tumor cells in the bone marrow - chances and consequences of microscopical detection methods.

Ruth Ladenstein, Peter F Ambros, Inge M Ambros, 2003, Cancer letters.

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Ruth Ladenstein, Henrik Schroeder, Ulrike Pötschger, 2018, The Lancet. Oncology.